Free Trial
ASX:DXB

Dimerix (DXB) Stock Price, News & Analysis

Dimerix logo

About Dimerix Stock (ASX:DXB)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
5.16%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. The company develops DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 which is in phase 2 clinical trial for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for chronic obstructive pulmonary disease, as well as develops proprietary receptor- HIT assay technology. Dimerix Limited is headquartered in Fitzroy, Australia.

Receive DXB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dimerix and its competitors with MarketBeat's FREE daily newsletter.

DXB Stock News Headlines

Companies Like Dimerix (ASX:DXB) Can Afford To Invest In Growth
Dimerix’s Phase 3 Kidney Trial Progresses Successfully
Free ebook reveals our #1 chart pattern for 2020, 2021, 2022, 2023 and 2024.
It's time to get smart… We think many good traders get caught up in the wrong stocks and ultimately burn up their trading accounts, which is why we want to share something special with you… You see, our top technical trader just published a new e-book sharing his #1 stock pattern for the last 4 years… It’s the same pattern that’s helped him grow his model portfolio by an average of 85% per year since 2020, and he’s currently giving away digital copies for free. Inside, he’ll walk you through his #1 pattern, and show you why it forms. As you’ll see, it’s all thanks to the algorithmic anomaly caused by Wall Street’s trading algorithms… It's the main reason, this pattern paid out more than 72% of the time.
Dimerix Gains $7.9 Million Boost for R&D Initiatives
Dimerix Collaborates with NEPTUNE for Trial Recruitment
See More Headlines

DXB Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Dimerix investors own include Immuron (IMRN), Noxopharm (NOX), Tabcorp (TAH), NexGen Energy (NXE) and Kazia Therapeutics (KZIA).

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-17,080,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$9.12 million
Book Value
A$0.03 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.53
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

This page (ASX:DXB) was last updated on 11/29/2024 by MarketBeat.com Staff
From Our Partners